AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20850778 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 27)
Number of subjects: 81
Study 17980364 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and orlistat (120 mg, 3 times per day) for 24 weeks
Number of subjects: 32
Study 15830222 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg
Number of subjects: 12
Study 15830222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12114416 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM486A at a maximum tolerated dose (MTD) of 102.4 mg/m2/day
Number of subjects: 23
Study 12114416 — intervention group
Group type: EXPERIMENTAL
Intervention: SAM486A
Number of subjects: 23
Study 10399774 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/day of 17 beta-estradiol via skin patch
Number of subjects: 12
Study 10399774 — intervention group
Group type: COMPARATOR
Intervention: Placebo skin patch
Number of subjects: 12
Study 7555469 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensively treated (HbA1c 7.1 +/- 1.2%)
Number of subjects: 16
Study 7555469 — intervention group
Group type: COMPARATOR
Intervention: Conventionally treated (HbA1c 9.0 +/- 1.5%)
Number of subjects: 16
Study 1574968 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion 1 mg kg‐1 h‐1 preceded by a 1 mg kg‐1 bolus
Number of subjects: 30
Study 1574968 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1 micrograms kg‐1 and diazepam 0.05 mg kg‐1
Number of subjects: 30
Study 1574968 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 4028905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.4 g/kg body weight
Number of subjects: 11
Study 4028905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.6 g/kg body weight
Number of subjects: 11
Study 4028905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.8 g/kg body weight
Number of subjects: 11
Study 31870384 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized home-based exercise and nutrition interventions
Number of subjects: 0
Study 31870384 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29636539 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 223
Study 29636539 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) intervention
Number of subjects: 223
Study 29636539 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dietary and PA interventions
Number of subjects: 223
Study 29636539 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 223
Study 26786710 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid plus subcutaneous injections of carbon dioxide
Number of subjects: 40
Study 26786710 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 40
Study 23241328 — intervention group
Group type: EXPERIMENTAL
Intervention: SofZia-preserved travoprost 0.004% (TravatanZ(®))
Number of subjects: 215
Study 23241328 — intervention group
Group type: COMPARATOR
Intervention: BAK-preserved latanoprost 0.005% (Xalatan(®))
Number of subjects: 215
Study 21307692 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge nursing intervention
Number of subjects: 0
Study 21307692 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 19049337 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/d for 12 months, then continued for another 12 months)
Number of subjects: 507
Study 19049337 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d for 12 months after teriparatide)
Number of subjects: 507
Study 19049337 — intervention group
Group type: COMPARATOR
Intervention: No active treatment (after teriparatide)
Number of subjects: 507
Study 17097942 — intervention group
Group type: EXPERIMENTAL
Intervention: Celsior solution (CS), n = 40
Number of subjects: 80
Study 17097942 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin solution (UW), n = 40
Number of subjects: 80
Study 15004581 — intervention group
Group type: EXPERIMENTAL
Intervention: SL biomicroscopy (SL/SL)
Number of subjects: 40
Study 15004581 — intervention group
Group type: COMPARATOR
Intervention: SL and TM (SL/TM)
Number of subjects: 40
Study 15004581 — intervention group
Group type: COMPARATOR
Intervention: Both SL and TM
Number of subjects: 40
Study 11709746 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 0
Study 11709746 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 0
Study 9417503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite in combination with intensive decongestive physical therapy
Number of subjects: 0
Study 8256080 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms salbutamol
Number of subjects: 0
Study 8256080 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg propranolol
Number of subjects: 0
Study 8256080 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8256080 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg salbutamol
Number of subjects: 0
Study 8256080 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micrograms isoprenaline
Number of subjects: 0
Study 8256080 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg atenolol
Number of subjects: 0
Study 3960242 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (cycling, walking and jogging) for 12 months
Number of subjects: 14
Study 3960242 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Number of subjects: 14
Study 29555665 — intervention group
Group type: COMPARATOR
Intervention: Control diet with 2300 mg Na
Number of subjects: 379
Study 29555665 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 379
Study 27801408 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor training combined with transcutaneous spinal cord stimulation (TSCS) and functional electrical stimulation (FES)
Number of subjects: 19
Study 27801408 — intervention group
Group type: COMPARATOR
Intervention: Locomotor training alone (Control group)
Number of subjects: 19
Study 24999799 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan plus CCB
Number of subjects: 5141
Study 24999799 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan plus diuretic
Number of subjects: 5141
Study 22884058 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Da-Cheng-Qi Decoction (DCQD)
Number of subjects: 42
Study 22884058 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 20354030 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥ 30 kg/m²)
Number of subjects: 1519
Study 20354030 — intervention group
Group type: COMPARATOR
Intervention: Non-obese patients (BMI 18.5-29.9 kg/m²)
Number of subjects: 1519
Study 18550978 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SG)
Number of subjects: 29
Study 18550978 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic stretching (BG)
Number of subjects: 29
Study 18550978 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 29
Study 15779642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepentol
Number of subjects: 331
Study 15779642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 15779642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepentol and Placebo
Number of subjects: 331
Study 11958353 — intervention group
Group type: EXPERIMENTAL
Intervention: go/no-go lexical decision task
Number of subjects: 0
Study 11958353 — intervention group
Group type: COMPARATOR
Intervention: yes/no lexical decision task
Number of subjects: 0
Study 10582256 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV (Non-invasive Positive Pressure Ventilation)
Number of subjects: 0
Study 10582256 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin administration
Number of subjects: 0
Study 7675973 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 10
Study 7675973 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 10
Study 7675973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2187668 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase administered intravenously as a bolus before hospital admission (group I, n = 40)
Number of subjects: 78
Study 2187668 — intervention group
Group type: COMPARATOR
Intervention: Urokinase administered intravenously as a bolus after hospital admission (group II, n = 38)
Number of subjects: 78
Study 6776316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnelling of PVC catheters (group B)
Number of subjects: 150
Study 6776316 — intervention group
Group type: COMPARATOR
Intervention: Direct puncture technique (group A)
Number of subjects: 150
Study 30039248 — intervention group
Group type: EXPERIMENTAL
Intervention: Food deprivation
Number of subjects: 0
Study 30039248 — intervention group
Group type: COMPARATOR
Intervention: Control stimuli
Number of subjects: 0
Study 30880212 — intervention group
Group type: EXPERIMENTAL
Intervention: Confluent bilateral cement (Group A)
Number of subjects: 1341
Study 30880212 — intervention group
Group type: COMPARATOR
Intervention: Separated bilateral cement (Group B)
Number of subjects: 1341
Study 30880212 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 1341
Study 28010943 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 40
Study 28010943 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery Technique (ET)
Number of subjects: 40
Study 25765536 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tryptophan
Number of subjects: 51
Study 25765536 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 51
Study 24346254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermasilk® briefs
Number of subjects: 30
Study 24346254 — intervention group
Group type: COMPARATOR
Intervention: Cotton placebo briefs
Number of subjects: 30
Study 21246077 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasted, silica coating via sol‐gel process prepared using 20 wt% silica sols, and then silane coupling agent applied (Group Al20C)
Number of subjects: 60
Study 21246077 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasted, silica coating via sol‐gel process prepared using 30 wt% silica sols, and then silane coupling agent applied (Group Al30C)
Number of subjects: 60
Study 21246077 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasted, silica coating via sol‐gel process prepared using 40 wt% silica sols, and then silane coupling agent applied (Group Al40C)
Number of subjects: 60
Study 21246077 — intervention group
Group type: COMPARATOR
Intervention: Sandblasted (Group Al)
Number of subjects: 60
Study 21246077 — intervention group
Group type: COMPARATOR
Intervention: Sandblasted + silane coupling agent applied (Group AlC)
Number of subjects: 60
Study 21246077 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups Al20C, Al30C, and Al40C
Number of subjects: 60
Study 21246077 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups after 20 days of water storage
Number of subjects: 60
Study 19384012 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 90
Study 19384012 — intervention group
Group type: COMPARATOR
Intervention: Ringer's Lactate (RL)
Number of subjects: 90
Study 17605780 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (5 mg, n = 43) every six hours for a total of four doses on the day preceding extubation
Number of subjects: 86
Study 17605780 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline, n = 43) every six hours for a total of four doses on the day preceding extubation
Number of subjects: 86
Study 17605780 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (5 mg, n = 43)
Number of subjects: 86
Study 17605780 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline, n = 43)
Number of subjects: 86
Study 15115173 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management asthma education based on the PRECEDE-PROCEED model
Number of subjects: 0
Study 15115173 — intervention group
Group type: COMPARATOR
Intervention: Regular outpatient asthma education (Control)
Number of subjects: 0
Study 15115173 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Experimental and Control)
Number of subjects: 0
Study 11795455 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 32 mg per day for 6 months
Number of subjects: 54
Study 11795455 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 54
Study 11795455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 9481027 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-specific serum IgE testing for six foods (milk, egg, wheat, soy, peanut, fish)
Number of subjects: 63
Study 9481027 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenges (36 double‐blind, placebo‐controlled, and 14 open)
Number of subjects: 63
Study 9481027 — intervention group
Group type: EXPERIMENTAL
Intervention: History of acute significant reactions
Number of subjects: 63
Study 9481027 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive levels of IgE
Number of subjects: 63
Study 7986245 — intervention group
Group type: EXPERIMENTAL
Intervention: Folsan tablet (5 mg folic acid)
Number of subjects: 17
Study 7986245 — intervention group
Group type: COMPARATOR
Intervention: Folsan injection solution (reference preparation B)
Number of subjects: 17
Study 2645385 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A: discontinue therapy
Number of subjects: 481
Study 2645385 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B: reinduction for 4 weeks, then discontinue therapy
Number of subjects: 481
Study 2645385 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen C: continue maintenance therapy for 2 more years, then discontinue
Number of subjects: 481
Study 2645385 — intervention group
Group type: COMPARATOR
Intervention: All regimens (A, B, C)
Number of subjects: 481
Study 2645385 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys randomized to discontinue therapy
Number of subjects: 481
Study 31574157 — intervention group
Group type: EXPERIMENTAL
Intervention: Dural Sealant Patch (DSP)
Number of subjects: 40
Study 31248390 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol in addition to therapeutic hypothermia
Number of subjects: 200
Study 31248390 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to therapeutic hypothermia
Number of subjects: 200
Study 31248390 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 200
Study 31248390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 28347919 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI and bevacizumab (TRIBE cohort)
Number of subjects: 453
Study 28347919 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI and bevacizumab (FIRE-3 cohort)
Number of subjects: 453
Study 28347919 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI and cetuximab (control cohort)
Number of subjects: 453
Study 26674187 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized serving-sizes in NFts
Number of subjects: 2010
Study 26674187 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptors or colour coding of % DV next to calories and nutrients in NFts
Number of subjects: 2010
Study 26674187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both standardized serving-sizes and descriptors of % DV in NFts
Number of subjects: 2010
Study 23291515 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Triple P
Number of subjects: 81
Study 23291515 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 81
Study 20381654 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-pro-BNP level > or = 260 pg/ml
Number of subjects: 206
Study 18420874 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium with bupivacaine (group MB)
Number of subjects: 108
Study 18420874 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (group B)
Number of subjects: 108
Study 18420874 — intervention group
Group type: COMPARATOR
Intervention: Magnesium (group M)
Number of subjects: 108
Study 18420874 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (group S)
Number of subjects: 108
Study 16647139 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality measures before and after treatment
Number of subjects: 95
Study 14563572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5FGF‐4 gene therapy
Number of subjects: 52
Study 14563572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 10821451 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-engineered surgical service; patients admitted on the day of surgery, guided by a clinical pathway, discharged early with domiciliary post-acute care.
Number of subjects: 0
Study 10821451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital in the Home care pathway; acute medical patients admitted through the Emergency Department.
Number of subjects: 0
Study 10821451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled results from both trials; treatment group from both trials.
Number of subjects: 0
Study 8888383 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (administered subcutaneously or by cigarette smoking)
Number of subjects: 0
Study 8888383 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (5 mg administered 90 min before testing)
Number of subjects: 0
Study 8888383 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified, but implied as subjects not receiving amphetamine)
Number of subjects: 0
Study 1892303 — intervention group
Group type: EXPERIMENTAL
Intervention: formoterol 12 micrograms twice a day
Number of subjects: 145
Study 1892303 — intervention group
Group type: COMPARATOR
Intervention: albuterol 200 micrograms four times a day
Number of subjects: 145
Study 6798902 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate
Number of subjects: 20
Study 6798902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31183535 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided pelvic floor muscle training (PFMT) program
Number of subjects: 48
Study 31183535 — intervention group
Group type: COMPARATOR
Intervention: Unguided pelvic floor muscle training (PFMT) program
Number of subjects: 48
Study 30927041 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1 mA for 30 min over auditory regions of temporal lobe)
Number of subjects: 24
Study 30927041 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 29388929 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective electrical stimulation using the 'LymphaVision' apparatus
Number of subjects: 42
Study 29388929 — intervention group
Group type: COMPARATOR
Intervention: Vermel electrophoresis with 1% sodium bromide solution
Number of subjects: 42
Study 25524559 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel strategy (group B) including access to a website, patient-targeted brochures, clinician-targeted education, and pocket referral cards.
Number of subjects: 820
Study 25524559 — intervention group
Group type: COMPARATOR
Intervention: Usual care (group A)
Number of subjects: 820
Study 25524559 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel strategy (group B)
Number of subjects: 820
Study 25362228 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH) dalteparin
Number of subjects: 2344
Study 25362228 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 2344
Study 22844152 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped numbers (TN) intervention
Number of subjects: 4
Study 22844152 — intervention group
Group type: EXPERIMENTAL
Intervention: Taped numbers (TN) intervention supplemented with performance feedback, reinforcement, and overcorrection
Number of subjects: 4
Study 19126117 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (0.08 microg kg(‐1) min(‐1))
Number of subjects: 12
Study 19126117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 12
Study 17260532 — intervention group
Group type: EXPERIMENTAL
Intervention: High sucrose diet (HD)
Number of subjects: 20
Study 17260532 — intervention group
Group type: COMPARATOR
Intervention: High fat diet (HFD)
Number of subjects: 20
Study 14749693 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide 100 microg/h infusion for 8 hours
Number of subjects: 12
Study 14749693 — intervention group
Group type: COMPARATOR
Intervention: Lanreotide 800 microg bolus injection
Number of subjects: 12
Study 11679509 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (100 mg on days 5-9)
Number of subjects: 40
Study 11679509 — intervention group
Group type: COMPARATOR
Intervention: Fertile women (control group)
Number of subjects: 40
Study 9129858 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (specific dosage and duration not mentioned)
Number of subjects: 0
Study 9129858 — intervention group
Group type: COMPARATOR
Intervention: Randomized recommendation to use or not use hormone therapy
Number of subjects: 0
Study 9129858 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion groups and questionnaires
Number of subjects: 0
Study 7955439 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 12
Study 7955439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3591257 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine (225-375 micrograms) + diazepam (5-15 mg)
Number of subjects: 63
Study 3591257 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 63
Study 3591257 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (300 mg the night before and 300 mg in the morning) + diazepam
Number of subjects: 63
Study 29478724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) for identification of ETT placement
Number of subjects: 32
Study 27658881 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-AD
Number of subjects: 240
Study 27658881 — intervention group
Group type: COMPARATOR
Intervention: ISP-AD
Number of subjects: 240
Study 27658881 — intervention group
Group type: COMPARATOR
Intervention: ETAU
Number of subjects: 240